Antihypertensive drugs and risk of COVID-19?,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antihypertensive drugs and risk of COVID-19?
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-03-26 , DOI: 10.1016/s2213-2600(20)30153-3
Christopher J Tignanelli ₁ , Nicholas E Ingraham ₂ , Matthew A Sparks ₃ , Ronald Reilkoff ₂ , Tamara Bezdicek ₄ , Bradley Benson ₅ , Timothy Schacker ₆ , Jeffrey G Chipman ₇ , Michael A Puskarich ₈

Affiliation

Lei Fang and colleagues suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the ACE2 receptor and that ACEIs and ARBs have the potential to upregulate ACE2. However, data for this mechanism are largely from animal studies of heart tissue. Human data have not consistently shown increased ACE2 levels.^,

中文翻译：

降压药和COVID-19的风险？

Lei Fang及其同事建议临床医生应考虑停用血管紧张素转化酶抑制剂（ACEIs）或血管紧张素受体阻滞剂（ARBs），因为冠状病毒病2019（COVID-19）患者的临床结局可能会增加，并且他们建议使用钙通道阻止程序作为替代。该建议背后的假设是，严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）的进入点是ACE2受体，ACEI和ARB可能会上调ACE2。但是，此机制的数据主要来自心脏组织的动物研究。人类数据未始终显示出ACE2水平升高。^，

更新日期：2020-03-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文